For the quarter ending 2025-09-30, KNSA had -$17,179K decrease in cash & cash equivalents over the period. $33,006K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 18,435 | 26,371 |
| Depreciation and amortization expense | 384 | 703 |
| Share-based compensation expense | 10,144 | 16,624 |
| Non-cash lease expense | 944 | 1,759 |
| Net amortization of premiums and accretion of discounts on short-term investments | -603 | 589 |
| Net gain on disposal of property and equipment | 43 | 24 |
| Deferred income taxes | 4,227 | 5,637 |
| Prepaid expenses and other current assets | -2,030 | 12,195 |
| Accounts receivable, net | 19,832 | -9,814 |
| Inventory | -6,785 | 21,817 |
| Other long-term assets | 143 | -1,975 |
| Accounts payable | -2,728 | 6,992 |
| Accrued expenses, accrued collaboration expenses and other current liabilities | 8,368 | 9,502 |
| Operating lease liabilities | -760 | -1,777 |
| Other long-term liabilities | 5,263 | 7,439 |
| Net cash provided by operating activities | 33,677 | 50,414 |
| Purchases of property and equipment | 671 | 264 |
| Purchases of short-term investments | 146,160 | 129,793 |
| Proceeds from the maturities of short-term investments | 84,076 | 74,633 |
| Net cash used in investing activities | -62,755 | -55,424 |
| Proceeds from issuance of class a ordinary shares under incentive award plans and employee share purchase plan | 16,252 | 15,925 |
| Payments in connection with ordinary shares tendered for employee tax obligations | 4,353 | 2,459 |
| Net cash provided by financing activities | 11,899 | 13,466 |
| Net decrease in cash and cash equivalents | -17,179 | 8,456 |
| Cash and cash equivalents at beginning of period | 183,581 | - |
| Cash and cash equivalents at end of period | 174,858 | - |
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)